Quarterly Results Results Snapshot
YoYQoQ
Figures in Cr
Consolidate Quarterly Results
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Net Sales
54.35
46.50
35.17
38.28
39.89
43.11
39.92
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
54.35
46.50
35.17
38.28
39.89
43.11
39.92
Raw Material Cost
27.43
18.55
17.30
19.64
16.19
22.35
21.25
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
-1.38
5.40
-2.29
-1.30
1.32
-0.58
-2.96
Employee Cost
7.38
7.01
6.94
6.67
6.50
6.27
6.80
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Expenses
11.60
6.80
8.65
8.42
8.12
6.82
7.75
Total Expenditure (Excl Depreciation)
45.03
37.76
30.60
33.43
32.13
34.86
32.84
Operating Profit (PBDIT) excl Other Income
9.32
8.74
4.57
4.85
7.76
8.25
7.08
Other Income
1.32
0.72
1.38
1.59
0.32
0.62
0.48
Operating Profit (PBDIT)
10.64
9.46
5.95
6.44
8.08
8.87
7.56
Interest
0.22
0.20
0.08
0.15
0.27
0.31
0.34
Exceptional Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
10.42
9.26
5.87
6.29
7.81
8.56
7.22
Depreciation
1.21
1.15
0.84
1.18
1.10
1.05
0.84
Profit Before Tax
9.22
8.11
5.03
5.10
6.72
7.52
6.37
Tax
2.36
1.95
1.26
1.30
1.71
1.82
1.53
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
6.86
6.16
3.77
3.80
5.00
5.70
4.84
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
6.86
6.16
3.77
3.80
5.00
5.70
4.84
Share in Profit of Associates
0.90
0.70
0.28
0.59
1.69
0.70
0.16
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
7.76
6.86
4.05
4.39
6.70
6.40
5.00
Equity Capital
8.26
8.26
8.26
8.26
8.26
8.26
8.26
Face Value
10.0
10.0
10.0
10.0
10.0
10.0
10.0
Reserves
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Earnings per share (EPS)
9.39
8.31
4.9
5.31
8.11
7.75
6.05
Diluted Earnings per share
9.4
8.3
4.9
5.31
8.1
7.74
6.05
Operating Profit Margin (Excl OI)
17.15%
18.8%
12.99%
12.67%
19.45%
19.14%
17.74%
Gross Profit Margin
19.17%
19.91%
16.69%
16.43%
19.58%
19.86%
18.09%
PAT Margin
12.62%
13.25%
10.72%
9.93%
12.53%
13.22%
12.12%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Sep 2025 is 36.25% vs -8.15% in Sep 2024
Consolidate Net Profit
YoY Growth in quarter ended Sep 2025 is 15.82% vs 2.76% in Sep 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Sep 2025 is 20.10% vs -11.01% in Sep 2024
Interest
YoY Growth in quarter ended Sep 2025 is -18.52% vs -3.57% in Sep 2024
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Sep 2025 has fallen from Sep 2024
Compare Quarterly Results Of Titan Biotech With
Figures in Cr
Consolidate Quarterly Results
Change(INR)
Change(%)
Net Sales
54.35
277.05
-222.70
-80.38%
Other Operating Income
0.00
0.00
0.00
Total Operating income
54.35
277.05
-222.70
-80.38%
Raw Material Cost
27.43
193.65
-166.22
-85.84%
Purchase of Finished goods
0.00
4.18
-4.18
-100.00%
(Increase) / Decrease In Stocks
-1.38
-17.14
15.76
91.95%
Employee Cost
7.38
15.91
-8.53
-53.61%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
11.60
48.47
-36.87
-76.07%
Total Expenditure (Excl Depreciation)
45.03
245.07
-200.04
-81.63%
Operating Profit (PBDIT) excl Other Income
9.32
31.98
-22.66
-70.86%
Other Income
1.32
4.91
-3.59
-73.12%
Operating Profit (PBDIT)
10.64
36.89
-26.25
-71.16%
Interest
0.22
6.06
-5.84
-96.37%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
10.42
30.83
-20.41
-66.20%
Depreciation
1.21
5.23
-4.02
-76.86%
Profit Before Tax
9.22
25.59
-16.37
-63.97%
Tax
2.36
7.48
-5.12
-68.45%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
6.86
18.11
-11.25
-62.12%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
6.86
18.11
-11.25
-62.12%
Share in Profit of Associates
0.90
0.00
0.90
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
7.76
18.11
-10.35
-57.15%
Equity Capital
8.26
36.29
-28.03
-77.24%
Face Value
10.00
5.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
9.39
2.50
6.89
275.60%
Diluted Earnings per share
9.40
2.50
6.90
276.00%
Operating Profit Margin (Excl OI)
17.15%
11.54%
0.00
5.61%
Gross Profit Margin
19.17%
11.13%
0.00
8.04%
PAT Margin
12.62%
6.54%
0.00
6.08%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Quarterly - Net Sales
Net Sales 54.35 Cr
in Sep 2025Figures in Cr
QoQ Growth in quarter ended Sep 2025 is 16.88% vs 32.21% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 36.25% vs -8.15% in Sep 2024
Quarterly - Consolidate Net Profit
Consolidate Net Profit 7.76 Cr
in Sep 2025Figures in Cr
QoQ Growth in quarter ended Sep 2025 is 13.12% vs 69.38% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 15.82% vs 2.76% in Sep 2024
Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 9.32 Cr
in Sep 2025Figures in Cr
QoQ Growth in quarter ended Sep 2025 is 6.64% vs 91.25% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 20.10% vs -11.01% in Sep 2024
Quarterly - Interest
Interest 0.22 Cr
in Sep 2025Figures in Cr
QoQ Growth in quarter ended Sep 2025 is 10.00% vs 150.00% in Jun 2025
YoY Growth in quarter ended Sep 2025 is -18.52% vs -3.57% in Sep 2024
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 17.15%
in Sep 2025Figures in %
QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025
YoY Growth in quarter ended Sep 2025 has fallen from Sep 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
